Looking at China Dongsheng International (OTCMKTS:CDSG) and Amarin (NASDAQ:AMRN)

Amarin ( NASDAQ:AMRN – Get Your Free Report ) and China Dongsheng International ( OTCMKTS:CDSG – Get Your Free Report ) are both small-cap medical companies, but which is the superior stock? We’ll compare the two companies based on the strength of profitability, valuation, risk, dividends, institutional ownership, analyst recommendations and earnings.

Analyst ratings

This is a summary of recent ratings and price targets for Amarin and China Dongsheng International as provided by MarketBeat.

Amarin currently has a consensus price target of $1.00, suggesting a potential upside of 65.51%. Given Amarin’s higher possible upside, equities analysts plainly believe Amarin is more favorable than China Dongsheng International.

Rating and Earnings

This table compares Amarin and China Dongsheng International’s revenue, earnings per share (EPS) and valuation.

China Dongsheng International has lower revenue but higher earnings than Amarin.

return

This table compares Amarin and China Dongsheng International’s net margins, return on equity and return on assets.

Insider and institutional ownership

22.3% of Amarin shares are owned by institutional investors. 2.0% of Amarin shares are held by insiders. Comparatively, 73.5% of China Dongsheng International shares are held by company insiders. Strong institutional ownership is an indication that big money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Volatility and risk

Amarin has a beta of 1.92, indicating that its share price is 92% more volatile than the S&P 500. Comparatively, China Dongsheng International has a beta of 15.25, indicating that its share price it is 1,425% more volatile than the S&P 500.

Summary

China Dongsheng International beats Amarin in 6 of the 10 factors comparing the two stocks.

About Amarin

(Get a free report)

Amarin Corporation plc, a pharmaceutical company, is engaged in the development and commercialization of drugs for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product used as a dietary adjunct to lower triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products mainly to wholesalers and specialty pharmacy suppliers. The company has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and market medicinal products and indications based on the active pharmaceutical ingredient in Vascepa. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was established in 1989 and is headquartered in Dublin, Ireland.

About China Dongsheng International

(Get a free report)

China Dongsheng International, Inc. engages in the acquisition, exploration and development of mineral properties. The company primarily explores lithium. It holds an 80% stake in the Titan Projects located in Tanzania; and has the right to earn a 60% interest in the West End Lithium Project near Tonopah Nevada. China Dongsheng International, Inc. is based in Las Vegas, Nevada.

Get news and reviews for Amarin Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Amarin and related companies with MarketBeat.com’s FREE daily email newsletter.